What is Coeptis Therapeutics Holdings, Inc. (COEP)?

Coeptis Therapeutics Holdings, Inc. (COEP) is a stock in the Technology sector, Software - Services industry. View full analysis on Stocks360.

What is the current price of COEP?

The current price of COEP is $10.99. Prices are updated in real time on Stocks360.

What is COEP's price-to-earnings (PE) ratio?

COEP's trailing twelve-month PE ratio is -6.11, based on current price and earnings per share data available on Stocks360.

What is COEP's market capitalization?

COEP's market capitalization is $38,617,102.00, placing it in the small-cap tier.

Coeptis Therapeutics Holdings, Inc. (COEP)

Stock analysis · NASDAQ · Technology · Software - Services

$10.99

Market Cap

$38.62M

PE (TTM)

-6.11

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.43

Day Range

$10.81 – $11.99

52-wk Range

$6.80 – $21.41

Avg Volume

N/A

Volume

408.20K

Coeptis Therapeutics Holdings, Inc. (COEP) is a publicly traded company in the Technology sector. Latest price: $10.99. Market cap $38.62M. Trailing PE -6.11. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $14.96 2026-04-24 · $16.40 (+9.63%)

Earnings

Most Recent

Mar 19, 2026

EPS $-0.12 vs est. $-0.80

Beat by $0.68

Proprietary Signals

Signal snapshot temporarily unavailable.

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-6.11×
P/S (TTM)	13.81×
P/B	4.13×
P/FCF (TTM)	-9.55×
EV / EBITDA	-1.12×
EV / Sales	8.27×
Earnings Yield	-4.03%
Free Cash Flow Yield	-10.47%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$23.12M
Revenue (TTM)	$2.80M
Net Income (TTM)	-$1.56M
Free Cash Flow (TTM)	-$3.54M
Net Debt	-$15.49M
Working Capital	$13.50M
Gross Margin	16.78%
Operating Margin	-792.87%
Net Margin	-788.80%
Return on Equity	-48.21%
Return on Invested Capital	-16.68%